On April 1, 2026, Gregory L. Weaver, the Chief Financial Officer of Altimmune (NASDAQ:ALT), purchased 10,000 shares of the company's common stock at approximately $3.15 per share. This transaction increased his total ownership to 38,078 shares. The purchase was reported under Form 4, and further details are available through the SEC filing.
Altimmune is a biopharmaceutical company focused on developing treatments for metabolic and liver diseases. Its key drug, pemvidutide, targets conditions like metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company plans to start a global phase III program for MASH in 2026, aiming for accelerated approval based on biopsy co-primary endpoints.
A significant milestone for Altimmune is the expected release of RECLAIM AUD data in the third quarter of 2026. This development is anticipated to be a major catalyst beyond the MASH program. However, Altimmune faces challenges, including the need for additional funding as phase III spending increases, which could lead to dilution risks for shareholders.
Altimmune projects its cash runway to extend into 2028, but the absence of a product revenue base means that its stock performance will likely depend heavily on clinical execution and funding strategies. The company has a negative price-to-earnings (P/E) ratio of -3.56, indicating it is not currently profitable. The price-to-sales ratio is extremely high at 6,716.17, suggesting the stock trades at a significant premium relative to its sales.
The enterprise value to sales ratio is 6,519.29, reflecting a high valuation compared to sales. The enterprise value to operating cash flow ratio is negative at -3.94, further indicating financial challenges. The earnings yield is negative at -28.06%, highlighting a lack of earnings relative to the stock price. Despite these challenges, Altimmune maintains a low debt-to-equity ratio of 0.16, suggesting conservative use of debt, and a strong current ratio of 18.55, indicating robust short-term financial health.
